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Highlights of the ESPEN-ESPGHAN-ECFS Guidelines on
Nutrition Care for Infants and Children With
Cystic Fibrosis
Michael Wilschanski, yChristian P. Braegger, zCarla Colombo, §Dimitri Declercq,
jjAlison Morton, Ruzha Pancheva, #Eddy Robberecht, Martin Stern, yyBirgitta Strandvik,
zzSue Wolfe, and §§Stephane M. Schneider
T he European Society for Clinical Nutrition and Metabolism(ESPEN) launched a process of developing updated guide-
lines on nutrition care for infants, children, and adults with cystic
fibrosis (CF). To that end, a group of experts systematically
reviewed the medical literature to summarize current knowledge
on epidemiology and pathophysiology, prevention, and treatment of
CF-related undernutrition. The group included representatives from
several European countries, physicians, dietitians, and educators, all
experts in the field of CF, and the guidelines coordinator. The group
recommended evidence-based guidelines on nutrition care for
infants, children, and adults with CF. The experts followed the
GRADE method, which was based on determinations of grade of
evidence and strength of recommendation. The European Society
for Paediatric Gastroenterology, Hepatology and Nutrition (ESP-
GHAN) and the European Society for Cystic Fibrosis (ECFS), who
are partners of these guidelines, reviewed the final manuscript, with
an external review for ESPGHAN. The reader of the Journal is
kindly invited to refer to the original article published in the June
2016 issue of Clinical Nutrition (1).
This summary will outline some of the recommendations on
nutrition care for infants and children with CF.
SCOPE OF THE PROBLEM
CF is a life-threatening autosomal recessive genetic disease,
caused by dysfunction of the cystic fibrosis transmembrane
conductance regulator (CFTR) protein. The incidence in
Caucasians is 1 in 3500 births. Defective or absent CFTR function
alters Naþ and Cl transport across excretory epithelia, which
contributes to both the morbidity and mortality of the disease. CF
prognosis is strongly associated with poor nutritional status.
Although the nutritional status of people with CF has improved
markedly over the past 2 decades, adequate nutrition still remains a
major problem for some. Indeed, according to the most recent
ECFS Patient Registry data, half of people with CF in Europe do
not achieve adequate nutritional status. People with CF who are
diagnosed early through newborn screening programs benefit
from earlier intervention. This gives the opportunity to minimize
nutritional deficits and is associated with positive nutritional out-
comes. To achieve the best possible outcome for each person with
CF, it is important to provide care that includes attention to
nutrition.
CAUSES OF UNDERNUTRITION IN CYSTIC
FIBROSIS
Undernutrition in CF results from a combination of con-
ditions—energy losses, high-energy needs, and inadequate nutrient
intake. The primary cause of energy loss is malabsorption, often
resulting from maldigestion due to insufficient release of pancreatic
enzymes into the intestinal lumen (exocrine pancreatic insuffi-
ciency). Energy losses are further worsened when digestive
abnormalities are associated with metabolic changes, for example,
intestinal inflammation, small intestinal bacterial overgrowth, low
bicarbonate output, impaired insulin secretion with a variable
degree of insulin resistance (CF-related diabetes), and impaired
liver function (CF-related liver disease).
Furthermore, energy needs are higher in people with CF and
pancreatic insufficiency in comparison with needs of healthy
individuals, an observation supported by measurement of high
resting energy expenditure in people with CF. Such high-energy
expenditure correlates strongly with pancreatic insufficiency,
although the mechanism remains unclear. Furthermore, high-
energy requirements have also been attributed to persistent lung
inflammation and infections associated with CF.
People with CF may be unable to consume sufficient energy
to overcome shortfalls due to inefficient energy use and increased
energy needs. Psychosocial issues, such as stress and treatment
noncompliance, may contribute to energy shortfalls. Pulmonary
inflammation, discomforts related to associated gastrointestinal
problems (gastroesophageal reflux, constipation, distal intestinal
From the Department of Pediatric Gastroenterology, Hadassah-Hebrew
University Medical Center, Jerusalem, Israel, the yDivision of Gastro-
enterology and Nutrition and Children’s Research Center, University
Children’s Hospital Zurich, Zurich, Switzerland, the zFondazione IRCC
Ca’ Granda, Ospedale Maggiore Policlinico (IRSS), Universita degli
Studi di Milano, Milan, Italy, the §Department of Pediatrics, CF Center,
Ghent University Hospital, Ghent, Belgium, the jjRegional Adult CF
Unit, St James’ University Hospital, Leeds, UK, the Department of
Hygiene, Faculty of Public Health, Prof Dr Paraskev Stoyanov Medical
University of Varna, Varna, Bulgaria, the #Department of Pediatric
Gastroenterology, Hepatology and Nutrition, University of Ghent, CF
Center, Princess Elizabeth Pediatric Hospital, Ghent, Belgium, theUniversity Children’s Hospital, University of Tubingen, Tubingen,
Germany, the yyDepartment of Bioscience and Nutrition, Karolinska
Institute, Novum, Stockholm, Sweden, the zzRegional Pediatric CF Unit,
The Leeds Children’s Hospital, Leeds, UK, and the §§Gastroenterology
and Clinical Nutrition, Archet University Hospital and University of
Nice Sophia-Antipolis, Nice, France.
Address correspondence and reprint requests to Michael Wilschanski,
MBBS, Department of Pediatric Gastroenterology, Hadassah-Hebrew
University Medical Center, PO Box 24035, Jerusalem, Israel
(e-mail: michaelwil@hadassah.org.il).
The authors have no conflicts of interest.
Copyright # 2016 by European Society for Pediatric Gastroenterology,
Hepatology, and Nutrition and North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition
DOI: 10.1097/MPG.0000000000001349
ORIGINAL ARTICLE: PANCREATOLOGY
JPGN  Volume 63, Number 6, December 2016 671
 Copyright © ESPGHAL and NASPGHAN. All rights reserved.
obstructive syndrome, bacterial overgrowth), and the adverse
effects of medications can also decrease appetite and interfere with
intake goals.
CONSEQUENCES OF UNDERNUTRITION IN
CYSTIC FIBROSIS
Undernutrition affects respiratory muscle function, decreases
exercise tolerance, and leads to immunological impairment.
Although CF pathophysiology is directly linked to a deficit of
energy intake relative to needs, CF also affects multiple body
systems in ways that further worsen pulmonary status, impair
growth, lower quality of life, and shorten life expectancy.
In infants and young children with CF, poor nutritional status
results in stunted growth, as detected by low weight- and height-for-
age percentiles. If untreated, such CF-related undernutrition in
infancy or early childhood can lead to the serious consequence
of impaired cognitive function. In cases of severe undernutrition in
infants and children, lung function worsens markedly, and survival
is poor.
As CF progresses in older children, a wide range of metabolic
complications cause nutritional deficits, which further compromise
quality of life and increase mortality risk. For example, CF-related
diabetes—insulin deficiency and/or insulin resistance—causes and
worsens malnutrition by lowering insulin’s anabolic effects. Sim-
ilarly, CF-related liver disease and hepatic steatosis are associated
with selective nutritional deficiencies, for example, fat-soluble
vitamins, essential fatty acids, and calcium, this in turn worsening
malnutrition and contributing to problems such as reduced bone
mineral density.
Taken together, such adverse consequences of nutrient def-
icits in infants and children with CF are a rationale for early and
aggressive nutrition intervention, beginning in the first years of life
and continuing over the lifespan of the patient.
A SYSTEMATIC APPROACH TO NUTRITIONAL
ASSESSMENT AND MONITORING IN CYSTIC
FIBROSIS
At all ages, individuals with CF are at nutritional risk;
therefore, routine and complete nutritional assessments are essential
to improve outcomes. For infants who are diagnosed by newborn
screening, attention to nutrition is key to maintaining normal
growth—even before signs of the CF phenotype become evident.
Criteria indicating adequate nutritional status are described
in Table 1; recommendations for nutritional assessment and follow-
up, and for energy requirements are shown in Tables 2 and
3, respectively.
PANCREATIC ENZYME REPLACEMENT
THERAPY
Pancreatic enzyme replacement therapy (PERT) is vital to
maintain adequate nutritional status in people with CF with
exocrine pancreatic insufficiency; the efficacy of this treatment
is well established. Recommendations for PERT are described in
Table 4.
FEEDING INFANTS AND CHILDREN WITH
CYSTIC FIBROSIS
Exclusive breast-feeding is recommended for newly diag-
nosed infants with CF, and the use of a regular infant formula if
breastfeeding is not possible (grade of evidence: low).
Dietary counseling is essential throughout early childhood
when long-term feeding habits are being established. Advice from a
CF dietitian should be tailored to the individuals’ age and evolving
independence, clinical status, and support the goal of self-care.
Nutrition education and behavioral counseling are recom-
mended for all families of infants and children with CF (grade of
evidence: high).
TABLE 1. Criteria indicating adequate nutritional status
Infants and children 2 years: 0 SD (50th percentile) of weight and length
for a healthy same-age population.
Children 2–18 years: 0 SD (50th percentile) of BMI for a healthy, same-age
population. Change in height percentile/SD score should be considered, as
stunted children can have a normal BMI. Any height measurement should
be interpreted taking parental height into consideration.
Lean body mass and bone mineral content are more sensitive indicators of
nutritional deficit than low BMI; low values predict impaired lung
function in children with CF.
BMI ¼ body mass index; CF ¼ cystic fibrosis; SD ¼ standard deviation.
TABLE 2. Recommendations for nutritional assessment and follow-up
For pancreatic-sufficient infants and children, it is suggested that an annual assessment of pancreatic function by fecal pancreatic elastase-1 determination, with
the test repeated when inadequate growth and/or nutritional status occur(s).
For children and adolescents, it is recommend assessing for pancreatic enzyme replacement therapy (PERT) need or adequacy of treatment by monitoring
growth, nutritional status, and gastrointestinal symptoms; monitoring is suggested every month for children, and every 3 months for adolescents (grade of
evidence: low).
For children, care managers are suggested to consider annual nutritional review with blood tests (blood count, iron status, plasma fat-soluble vitamin levels,
serum liver function tests, and electrolyte measurements). Plasma phospholipids or red blood cell fatty acids can be monitored if the assay is available (grade
of evidence: low).
Annual screening of all people with CF at 10 years of age is recommended for glucose tolerance (grade of evidence: low).
It is recommended that children and adolescents undergo dietary review at least every 3 mo, including questions about adherence to dietary advice (grade of
evidence: low).
It is recommended to assess calcium intake at least annually (grade of evidence: low).
It is recommended to assess bone mineral density using dual-energy x-ray absorptiometry (DXA) in all people with CF from 8 to 10 years of age and then every
1 year to 5 years, depending on the age of the patient, value of the previous scan, and presence of risk factors (eg, physical inactivity, glucocorticoid therapy).
For patients younger than 20 years of age whose height is more than 1 standard deviation below age- and sex-matched healthy controls bone mineral density z
score should be adjusted for height or statural age to avoid overestimating deficits in bone mineral density in people with short stature.
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Fat-Soluble Vitamin Deficiency
Fat-soluble vitamin deficiency is common, occurring in 10%
to 35% of children with pancreatic insufficiency. It is unusual,
however, for people with CF to show clinical signs of overt
deficiency. Instead, the goal of evaluation and treatment is to
correct suboptimal levels and achieve optimal biochemical values
of these vitamins.
For pancreatic insufficient patients, it is recommended to
evaluate plasma levels of fat-soluble vitamins after initiation of
enzyme and vitamin supplementation; 3 to 6 months after initiation
or change in vitamin therapy; and annually thereafter. Vitamin
supplements should be taken together with high-fat food and
pancreatic enzyme supplements to improve absorption. When
biochemical deficiency is detected despite adequate vitamin supple-
mentation, poor adherence or poor absorption of supplements must
be ruled out before adjusting the dosage. For pancreatic sufficient
patients, it is recommended to assess vitamin sufficiency annually
using plasma levels.
In recent years the adequacy of vitamin D supplementation in
CF has received considerable attention. Vitamin D plays a major
role in intestinal calcium absorption, and deficiency of this vitamin
is one of several factors that can contribute to reduced bone mineral
density in people with CF. The major source of vitamin D, exposure
of skin to sunlight, can vary widely between individuals and
available sunlight, which in turn depends on geographical latitude.
The best indicator of vitamin D status is serum 25-hydroxy vitamin
D (25[OH]D).
Vitamin D deficiency is common and has been reported in
22% of infants with CF at newborn screening; and > 90% of older
children and young adults with CF were found to have suboptimal
levels of 25(OH)D in 1 study. Table 5 shows the recommendations
for fat-soluble vitamin supplementation.
It is suggested to supplement children with CF with vitamin
D to maintain serum 25(OH)D concentrations >20 ng/mL (50
nmol/L). The supplemental dose should take into consideration
dietary intake and sunlight exposure of the individual patient.
Although there is some debate, vitamin D3 is preferred over D2
for supplementation in people with CF. Serum monitoring of
25(OH)D is recommended annually, preferably at the end of dark
months, and 3 to 6 months after a dosage change.
Electrolytes, Minerals, and Trace Elements
People with CF may have higher than normal requirements
for salt, calcium, iron, zinc, and selenium as a consequence of the
increased sweating, intestinal malabsorption, and chronic inflam-
mation that are common in CF.
Excessive salt loss in sweat can result in inadequate levels of
sodium in people with CF of all ages, and may lead to impaired
growth in infants. Zinc status in people with CF has been variously
reported as adequate and low. Zinc deficiency can be associated
with a broad range of symptoms in CF, including growth retar-
dation, increased susceptibility to infections, delayed sexual matu-
ration, eye problems, and anorexia caused by reduced sense of
taste (hypogeusia). Recommendations for sodium (as sodium
chloride) and zinc supplementation are described in Tables 6 and
7, respectively.
NUTRITION INTERVENTION
It is recommended to base nutrition intervention on a full
review of nutrition status, including a detailed review of PERT, and
correction of any underlying medical conditions (grade of evidence:
high).
It is recommended to use age-appropriate body mass index–
related thresholds for deciding when to advance nutrition interven-
tion (grade of evidence: high).
A progressive approach to intensification of nutrition inter-
ventions as needs increase is recommended: preventive nutritional
counseling, dietary modification and/or oral nutrition supplements,
and enteral tube feeding (grade of evidence: low).
Clinicians are recommended to consider the use of oral
nutritional supplements for treating children and adults who fail
to achieve optimal growth rates and nutritional status with oral
dietary intake and pancreatic enzyme replacement therapy (PERT)
alone (grade of evidence: low).
Recommendations for sodium (as sodium chloride) and zinc
supplementation are status with oral dietary intake and PERT alone
(grade of evidence: low).
Clinicians are recommended to consider the use of polymeric
enteral tube feeding when oral interventions have failed to achieve
acceptable rates of growth and nutritional status (grade of evidence:
high).
Although additional research trials will strengthen the evi-
dence base for many recommendations, there is a specific need for
TABLE 3. Recommendations for energy requirements
Age Energy target Detail
Infants and children 2
years or younger
110%–200% of
energy
requirements for
same-age healthy
infants and children
Energy intake should
be adapted to
achieve normal
weight- and length-
for-age percentiles
Children 2–18 years 110%–200% of
energy
requirements for
same-age healthy
children
Energy intake should
be adapted to
achieve target BMI
percentile tailored
to 1-year age
intervals
TABLE 4. Recommendations for pancreatic enzyme replacement
therapy
Age Suggested supplementation
Infants (up to 12
months)
2000–4000 U lipase/120 mL formula or
estimated breast milk intake and
approximately 2000 U lipase/gram dietary
fat in food
Children 1–4 years 2000–4000 U lipase/gram dietary fat,
increasing dose upward as needed
(maximum dose 10,000 U lipase/kg per
day)
Children>4 years and
adults
Consider starting at 500 U lipase/kg per meal,
titrating upward to a maximal dose of:
1000–2500 U lipase/kg per meal, or
10,000 U lipase/kg per day, or
2000–4000 U lipase/gram dietary fat taken
with all fat-containing meals, snacks, and
drinks
Seventy-two-hour fecal fat measurement and the calculation of the
coefficient of fat absorption may be used in patients whose nutritional
status is questionable.
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TABLE 5. Fat-soluble vitamin guidelines for pancreatic insufficient patients with cystic fibrosis¼ consensus guidelines
Vitamin Supplementation Serum reference values and monitoring frequency
Fat-soluble vitamins
Vitamin A Amounts dependent on serum values, and
supplement form:
Normal reference range provided by the laboratory
processing the sample
Retinol (preformed):
Start low Monitor annually and 3–6 mo after a dosage change.
Also test when pregnancy is considered.
Adapt rapidly to target normal serum reference
range
Beta-carotene (provitamin A):
Prescribe 1 mg  kg1  day1 (maximum 50 mg/
day) for 12 wk
Follow with maintenance dose (maximum 10 mg/
day)
Vitamin D Dependent on serum values, which vary with
dietary intake and sun exposure:
Serum-25 (OH) D minimum 20 ng/mL (50 nmol/L)
Starting dose of D3 (cholecalciferol) Monitor annually, and check 3–6 months after a
dosage change
Infants 400 IU/day (advance to upper limit of 1000
IU/day)
All others 800 IU/day (advance to upper limit of
2000 for children 1–10 years, and 4000 IU/day for
older)
Maintenance dose: adapt to annual serum values,
preferably measured at the end of dark months
Vitamin E
(tocopherols)
a-Tocopherol dosing: 100–400 IU/day 50 IU/day for
infants <12 mo (1 mg¼ 1.49 IU)
Plasma a-tocopherol:cholesterol ratio >5.4 mg/g;
monitor annually, and check 3–6 mo after a
dosage change
Vitamin K Vitamin K1 Routine biochemical measurement not widely
available
Infants: 0.3–1.0 mg/day
Older children and adults: 1–10 mg/day
Water-soluble vitamins
Folic acid Women planning to become pregnant, and during first trimester of pregnancy: 400 mg/day
Vitamin B12 May need supplementation after extensive ileal resection.
When deficient: 100 mg/mo, intramuscular injection
Vitamin C Supplement only when nutritional intake is insufficient
25(OH)D ¼ 25-hydroxyvitamin D.
TABLE 6. Recommendations for sodium supplementation (as sodium chloride) in children with cystic fibrosis (grade of evidence: moderate)
Age Sodium supplementation Detail
Breast-fed infants 0–6 months 1–2 mmol  kg1  day1 For infants at risk of sodium deficiency give salt in small portions
throughout the day, diluted in water or fruit juice.
For infants with special
considerations (see detail, right)
Up to 4 mmol/kg/day Increase intake for infants living in hot ambient temperatures; or for those
with increased fluid loss due to vomiting, fever, diarrhea, or tachypnea; or
infants with ostomies.
Older children and adolescents Salty foods or sodium chloride
capsules or vials
Supplement in stress situations when excessive sweating is expected (ie,
fever, exercise/sports, hot weather).
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studies on new treatments for nutritional complications of specific
fatty acids, antiosteoporotic agents, anti-inflammatory agents, ana-
bolic therapies, and probiotics.
CONCLUSIONS
Nutritional care and support should be an integral part of
management of CF. Obtaining a normal growth pattern in infants,
children, and adolescents is a major goal of multidisciplinary
CF centers.
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TABLE 7. Recommendations for zinc supplementation in children with cystic fibrosis
Age Recommended supplementation Recommended dosing period, mo
Infants and children younger than 2 year and at risk of zinc insufficiency 1 mg  kg1  day1 (max 15 mg/day) 6
Children 2–18 years and at risk of zinc insufficiency 15 mg/day 6
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